Prosight Management, LP Biomea Fusion, Inc. Transaction History

Prosight Management, LP

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$4.14 - $15.3 $204,420 - $755,468	49,377 Added 65.84%	124,377 $559,000
Q1 2024 May 15, 2024	BUY	$13.92 - $19.5 $445,565 - $624,175	32,009 Added 74.46%	75,000 $1.12 Million
Q4 2023 Feb 14, 2024	SELL	$8.37 - $19.8 $433,783 - $1.03 Million	-51,826 Reduced 54.66%	42,991 $624,000
Q3 2023 Nov 14, 2023	BUY	$13.44 - $23.02 $1.27 Million - $2.18 Million	94,817 New	94,817 $1.3 Million
Q4 2022 Feb 14, 2023	BUY	$6.3 - $11.6 $516,014 - $950,121	81,907 New	81,907 $690,000

104

17.8M

1.68M

410K

Ticker BMEA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 29,290,600
Market Cap $202M
Description
Biomea Fusion, Inc., a biopharmaceutical company, focuses on the discovery and development of covalent small molecule drugs to treat patients with genetically defined cancers and metabolic diseases. Its lead product candidate is BMF-219, an orally bioavailable, potent, and selective covalent inhibitor of menin, a transcriptional regulator in onc...

Get notified when there are updates to the investment portfolio of Prosight Management, LP, based on Form 13F filings with the SEC.

Stay updated on Prosight Management, LP with notifications on news.